Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences
February 17 2021 - 7:00AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat rare seizure disorders, today announced that Scott
Braunstein, M.D., Chief Executive Officer and Joseph Hulihan, M.D.,
Chief Medical Officer will present a corporate overview during the
10th Annual SVB Leerink Global Healthcare Conference on February 25
at 1:40 PM Eastern Standard Time. Company management will also
participate in the Cowen 41st Annual Health Care Conference on
March 1 at 10:20 AM (EST), the H.C. Wainwright Global Life Sciences
Conference on March 9 at 3:00 PM (EST), and the Oppenheimer 31st
Annual Healthcare Conference on March 16 at 8:00 AM (EST).
Additional details can be found below:
10th Annual SVB Leerink Global Healthcare Conference
- Date and Time: Thursday, February 25 at 1:40 PM (EST)
- Speakers: Scott Braunstein, M.D., Chief Executive Officer and
Joseph Hulihan, M.D., Chief Medical Officer
Cowen 41st Annual Health Care Conference
- Date and Time: Monday, March 1 at 10:20 AM (EST)
- Speakers: Scott Braunstein, M.D., Chief Executive Officer and
Joseph Hulihan, M.D., Chief Medical Officer
H.C. Wainwright Global Life Sciences Conference
- Date and Time: Accessible Tuesday, March 9 at 3:00 PM
(EST)
- Speaker: Scott Braunstein, M.D., Chief Executive Officer
Oppenheimer's 31st Annual Healthcare Conference
- Date and Time: Tuesday, March 16 at 8:00 AM (EST)
- Speakers: Scott Braunstein, M.D., Chief Executive Officer and
Joseph Hulihan, M.D., Chief Medical Officer
Webcasts may be accessed through the Events & Presentations
page of the Investors & Media section of Marinus website,
www.marinuspharma.com.
About Marinus Pharmaceuticals Marinus Pharmaceuticals,
Inc. is a pharmaceutical company dedicated to the development of
innovative therapeutics to treat rare seizure disorders. Ganaxolone
is a positive allosteric modulator of GABAA receptors that acts on
a well-characterized target in the brain known to have
anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone
is being developed in IV and oral dose forms intended to maximize
therapeutic reach to adult and pediatric patient populations in
both acute and chronic care settings. Marinus recently completed
the first ever Phase 3 pivotal trial in children with CDKL5
deficiency disorder and is conducting a Phase 2 trial in tuberous
sclerosis complex, as well as a Phase 2 biomarker-driven
proof-of-concept trial in PCDH19-related epilepsy. The company is
conducting a Phase 3 trial in status epilepticus. For more
information visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005187/en/
Sasha Damouni Ellis Vice President, Investor Relations &
Corporate Communications Marinus Pharmaceuticals, Inc. 484-253-6792
sdamouni@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024